about
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic TransplantationActivated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.Whole exome sequencing to estimate alloreactivity potential between donors and recipients in stem cell transplantation.Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor-Recipient Pairs.Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding.Dose intense therapy for relapsed lymphoproliferative disorders: the more things change, the more they are the same.Immunotherapy of cancer: reprogramming tumor-immune crosstalk.Etiology of GVHD: alloreactivity or impaired cellular adaptation?Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivity.Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.Treatment of acute fibrinous organizing pneumonia following hematopoietic cell transplantation with etanerceptIncreased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.Infections during mobilizing chemotherapy and following autologous stem cell transplantation.Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma.Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation.Fractal organization of the human T cell repertoire in health and after stem cell transplantation.Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis.Conditioning neoadjuvant therapies for improved immunotherapy of cancer.DNA nanomapping using CRISPR-Cas9 as a programmable nanoparticle.Dynamical system modeling to simulate donor T cell response to whole exome sequencing-derived recipient peptides: Understanding randomness in alloreactivity incidence following stem cell transplantation.Infection--an underappreciated cause of bone pain in multiple myelomaPreceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor aloneHigh response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsPredicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplantsABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioningAcquired factor VII deficiency in hematopoietic stem cell transplant recipientsAlefacept in corticosteroid refractory graft versus host disease: early results indicate promising activityThe administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failurePost-transplant air-leak syndromeSecond allografts for relapsed hematologic malignancies: feasibility of using a different donorFeasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCTPatients' understanding of disease status and treatment plan at initial hematopoietic stem cell transplantation consultation
P50
Q34338377-6821751F-9960-498C-A445-606F1EAD7893Q34462528-DCF10B29-04D4-4AC9-8446-77FB9FF5264EQ35091491-C715434F-963E-4CE9-A518-2D9BFDD393A3Q35153382-29B647D5-3329-48FF-B216-B5638002ED3FQ36812102-C3AFCC29-7C24-4269-B33E-96E489DA0C8CQ37114320-E072F7DF-64DC-4292-8D78-20EEF2E07ACEQ37170767-48A9A32E-4988-45AF-8DDD-860A00863DA6Q37393189-C5603D7C-3078-40A8-8757-0CC4B8C95B98Q37487759-03BFC827-6DF6-4AFC-B855-1F7B2CA5286CQ38055479-86F18901-0378-4B4C-A9B1-0D1CF7619B62Q38258160-41002D81-994C-488E-B0C2-D150949372AFQ38292672-1A90DE88-385C-4140-A83A-1F2FD64FCAD4Q38436359-F766CDFC-4070-49EE-9BDA-54F71B99C2ECQ38730411-9A46AE3E-3A19-4359-AAC5-B294D36624ACQ40096975-923F89F7-E478-4A41-8D9E-B9180DA0B1A8Q40369741-7C13445B-80A5-4F55-A22D-69428E36BA5FQ40963868-E907045A-7748-490E-A695-BB9DA9ECE02DQ43718558-02CA7736-EC23-4560-83C2-03A555BF086EQ43756553-3F2B95D2-80E6-445B-88F6-CBBBFC9514F1Q43861734-29DC48F8-6198-4AFD-B9E9-A4B9D4F2D983Q43954595-C45778E1-A786-4D9E-B998-4CC4A064FA9CQ44791851-B028D9EC-C047-4CD7-AC57-F2FCD78B465FQ44973515-E806CBAA-5832-4AC0-9B3E-E65E35418636Q44982162-9E930339-10EE-403F-86EC-C285B3F0854DQ45060240-5920F6B5-ED17-45A8-9613-3B099D56F01AQ45065285-255F4617-EBFF-4DB4-A7A2-F7738ECB068AQ45073610-2371E0C9-A3F9-431A-A92E-5B0616089359Q45074498-EB608F4A-4AFD-4B07-96B8-9A4F37F5DCCCQ73152577-AE4EA8E5-0D38-437F-BC9E-6429745666DBQ73416630-8E7D5491-0491-452E-A4F1-FFDDF745C3CEQ73784903-8682E99A-6A5E-4B4D-ABC1-0601E41832A2Q77631351-47DA1107-E738-46CD-9723-41BA96F9EE4EQ77769072-DE6B9D26-D49A-42E5-B99A-6EF6E4ACA45EQ77837427-05E29A92-1ED3-4784-90FA-862B3A15E1B5Q79964851-0089093E-C236-466E-9A32-DC6B412E388FQ80160600-BF7E395C-2CE6-4137-96B9-B6164A1D7D16Q80536908-DE142D32-0007-45A0-B240-678C67A72C84Q81042760-C95A5AC3-66BD-48B4-99C5-9B2161C30B96Q81798728-7A2B46DC-ADC1-40CA-BA1B-FC49D62C36EAQ82363839-2D20C0B0-1395-4390-B073-286904D38677
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amir A Toor
@ast
Amir A Toor
@en
Amir A Toor
@es
Amir A Toor
@nl
type
label
Amir A Toor
@ast
Amir A Toor
@en
Amir A Toor
@es
Amir A Toor
@nl
prefLabel
Amir A Toor
@ast
Amir A Toor
@en
Amir A Toor
@es
Amir A Toor
@nl
P106
P1153
7004178751
P31
P496
0000-0001-5317-8433